La Jolla Pharmaceutical (NASDAQ:LJPC) and Tetraphase Pharmaceuticals (NASDAQ:TTPH) have entered into a definitive merger agreement, under which La Jolla would acquire Tetraphase, through a tender offer, for $43M in upfront cash plus potential future cash payments of up to $16M pursuant to contingent value rights (CVRs).
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,